RT Journal Article
SR Electronic
T1 Estimating the size of COVID-19 epidemic outbreak
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.03.28.20044339
DO 10.1101/2020.03.28.20044339
A1 Pongkitivanichkul, Chakrit
A1 Samart, Daris
A1 Tangphati, Takol
A1 Koomhin, Phanit
A1 Pimton, Pimchanok
A1 Dam-O, Punsiri
A1 Payaka, Apirak
A1 Channuie, Phongpichit
YR 2020
UL http://medrxiv.org/content/early/2020/03/31/2020.03.28.20044339.abstract
AB In this work, we analyze the epidemic data of cumulative infected cases collected from many countries as reported by WHO starting from January 21st 2020 and up till March 21st 2020. Our inspection is motivated by the renormalization group (RG) framework. Here we propose the RG-inspired logistic function of the form as an epidemic strength function with n being asymmetry in the modified logistic function. We perform the non-linear least-squares analysis with data from various countries. The uncertainty for model parameters is computed using the squared root of the corresponding diagonal components of the covariance matrix. We carefully divide countries under consideration into 2 categories based on the estimation of the inflection point: the maturing phase and the growth-dominated phase. We observe that long-term estimations of cumulative infected cases of countries in the maturing phase for both n = 1 and n ≠ 1 are close to each other. We find from the value of root mean squared error (RMSE) that the RG-inspired logistic model with n ≠ 1 is slightly preferable in this category. We also argue that n determines the characteristic of the epidemic at an early stage. However, in the second category, the estimated asymptotic number of cumulative infected cases contain rather large uncertainty. Therefore, in the growth-dominated phase, we focus on using n = 1 for countries in this phase. Some of them are in an early stage of an epidemic with an insufficient amount of data leading to a large uncertainty on parameter fits. In terms of the accuracy of the size estimation, the results do strongly depend on limitations on data collection and the epidemic phase for each country.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo fundingAuthor DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe authors have declared no competing interest.